Trial Profile
A prospective phase I/II, one-arm, multi-center, open label study of pioglitazone in combination with sorafenib and low dose IFN alpha in metastatic, non-resectable renal clear cell carcinoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 08 May 2013
Price :
$35
*
At a glance
- Drugs Pioglitazone (Primary) ; Sorafenib (Primary) ; Interferon alpha-2a
- Indications Renal cell carcinoma
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 02 May 2012 New trial record